Navigation Links
About 60 Clinical Studies Regarding Schering-Plough's Oncology Compounds Will be Presented at ASCO
Date:5/30/2008

KENILWORTH, N.J., May 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced today that about 80 posters, poster discussions, and oral presentations from about 60 clinical studies relating to its growing oncology franchise will be presented at the upcoming 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30 - June 3. Data will be presented on TEMODAR(R) (temozolomide) Capsules, CAELYX(R) (pegylated liposomal doxorubicin hydrochloride), INTRON(R) A (Interferon alfa-2b, recombinant) for Injection and peginterferon alfa-2b, as well as the company's investigational oncology compounds including SCH 727965.

-- TEMODAR(R): Twenty-eight abstracts will be presented, including 10

poster discussions and eight oral presentations.

-- CAELYX(R): Eleven abstracts will be presented, including two poster

discussions and two oral presentations.

-- INTRON(R) A and peginterferon alfa-2b: Data will be featured in more

than 10 abstracts, including five poster discussions and five oral

presentations.

Please see important full U.S. Prescribing Information, and the Medication Guides for INTRON(R) A and peginterferon alfa-2b at http://www.schering-plough.com.

Schering-Plough Corp. has exclusive ex-U.S. marketing rights to CAELYX(R), except in Japan and Israel, through a distribution agreement with ALZA, a wholly owned subsidiary of Johnson & Johnson, New Brunswick, N.J., USA. The product is marketed in the United States under the tradename DOXIL(R) by Ortho Biotech Products, L.P. Full EU Prescribing Information may be accessed at http://www.emea.europa.eu/humandocs/PDFs/EPAR/Caelyx/H-089-PI-en.pdf.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market and the clinical development of its oncology portfolio. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part I, Item 1A, "Risk Factors" in Schering-Plough's 2008 Q1 10-Q.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
2. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
3. Second Thoughts about Fluoride, Reports Scientific American
4. Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee
5. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
6. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
7. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
8. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
9. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
10. AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
11. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):